# HCRN GU22-598 (NCT06809140)

> Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06809140
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Matthew Galsky
- Conditions: Muscle Invasive Bladder Urothelial Carcinoma
- Interventions: Enfortumab vedotin; Pembrolizumab
- Enrollment: 75
- Primary outcome: Complete response rate with enfortumab vedotin plus pembrolizumab for MIBC
- Primary outcome: Bladder-intact event-free survival (BIEFS) in patients achieving a clinical complete response

## Indexed commentary on HCRN GU22-598 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=hcrn-gu22-598-nct06809140